<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34948077</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>18</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>24</Issue><PubDate><Year>2021</Year><Month>Dec</Month><Day>10</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Immune Signaling Kinases in Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD).</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">13280</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms222413280</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is the most common neurodegenerative disorder of motor neurons in adults, with a median survival of 3-5 years after appearance of symptoms, and with no curative treatment currently available. Frontotemporal dementia (FTD) is also an adult-onset neurodegenerative disease, displaying not only clinical overlap with ALS, but also significant similarities at genetic and pathologic levels. Apart from the progressive loss of neurons and the accumulation of protein inclusions in certain cells and tissues, both disorders are characterized by chronic inflammation mediated by activated microglia and astrocytes, with an early and critical impact of neurodegeneration along the disease course. Despite the progress made in the last two decades in our knowledge around these disorders, the underlying molecular mechanisms of such non-cell autonomous neuronal loss still need to be clarified. In particular, immune signaling kinases are currently thought to have a key role in determining the neuroprotective or neurodegenerative nature of the central and peripheral immune states in health and disease. This review provides a comprehensive and updated view of the proposed mechanisms, therapeutic potential, and ongoing clinical trials of immune-related kinases that have been linked to ALS and/or FTD, by covering the more established TBK1, RIPK1/3, RACK I, and EPHA4 kinases, as well as other emerging players in ALS and FTD immune signaling.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Garc&#xed;a-Garc&#xed;a</LastName><ForeName>Raquel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>CABIMER-Andalusian Center for Molecular Biology &amp; Regenerative Medicine, University Seville-CSIC-UPO, 41092 Seville, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Biochemistry, Molecular Biology and Immunology, University of Seville, 41009 Seville, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mart&#xed;n-Herrero</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>CABIMER-Andalusian Center for Molecular Biology &amp; Regenerative Medicine, University Seville-CSIC-UPO, 41092 Seville, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Biochemistry, Molecular Biology and Immunology, University of Seville, 41009 Seville, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blanca-Pariente</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>CABIMER-Andalusian Center for Molecular Biology &amp; Regenerative Medicine, University Seville-CSIC-UPO, 41092 Seville, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Biochemistry, Molecular Biology and Immunology, University of Seville, 41009 Seville, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>P&#xe9;rez-Cabello</LastName><ForeName>Jes&#xfa;s</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>CABIMER-Andalusian Center for Molecular Biology &amp; Regenerative Medicine, University Seville-CSIC-UPO, 41092 Seville, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Biochemistry, Molecular Biology and Immunology, University of Seville, 41009 Seville, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roodveldt</LastName><ForeName>Cintia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>CABIMER-Andalusian Center for Molecular Biology &amp; Regenerative Medicine, University Seville-CSIC-UPO, 41092 Seville, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Biochemistry, Molecular Biology and Immunology, University of Seville, 41009 Seville, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>RTI2018-098432-B-I00</GrantID><Agency>Ministry of Economy, Industry and Competitiveness</Agency><Country/></Grant><Grant><GrantID>CIVP19A5938</GrantID><Agency>Fundaci&#xf3;n Ram&#xf3;n Areces</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 2.7.-</RegistryNumber><NameOfSubstance UI="D010770">Phosphotransferases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007107" MajorTopicYN="N">Immune System</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="Y">Inflammation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010770" MajorTopicYN="N">Phosphotransferases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="Y">Signal Transduction</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis (ALS)</Keyword><Keyword MajorTopicYN="N">drug</Keyword><Keyword MajorTopicYN="N">frontotemporal dementia (FTD)</Keyword><Keyword MajorTopicYN="N">immune</Keyword><Keyword MajorTopicYN="N">inhibitor</Keyword><Keyword MajorTopicYN="N">kinase</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">neuroinflammation</Keyword><Keyword MajorTopicYN="N">signaling</Keyword><Keyword MajorTopicYN="N">therapy</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>10</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>12</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>12</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>24</Day><Hour>1</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34948077</ArticleId><ArticleId IdType="pmc">PMC8707599</ArticleId><ArticleId IdType="doi">10.3390/ijms222413280</ArticleId><ArticleId IdType="pii">ijms222413280</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Caballero-Hernandez D., Toscano M.G., Cejudo-Guillen M., Garcia-Martin M.L., Lopez S., Franco J.M., Quintana F.J., Roodveldt C., Pozo D. The &#x201c;Omics&#x201d; of Amyotrophic Lateral Sclerosis. Trends Mol. Med. 2016;22:53&#x2013;67. doi: 10.1016/j.molmed.2015.11.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2015.11.001</ArticleId><ArticleId IdType="pubmed">26691296</ArticleId></ArticleIdList></Reference><Reference><Citation>Jimenez-Pacheco A., Franco J.M., Lopez S., Gomez-Zumaquero J.M., Magdalena Leal-Lasarte M., Caballero-Hernandez D.E., Cejudo-Guill&#xe9;n M., Pozo D. Epigenetic Mechanisms of Gene Regulation in Amyotrophic Lateral Sclerosis. Adv. Exp. Med. Biol. 2017;978:255&#x2013;275. doi: 10.1007/978-3-319-53889-1_14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-319-53889-1_14</ArticleId><ArticleId IdType="pubmed">28523551</ArticleId></ArticleIdList></Reference><Reference><Citation>McCauley M.E., Baloh R.H. Inflammation in ALS/FTD pathogenesis. Acta Neuropathol. 2019;137:715&#x2013;730. doi: 10.1007/s00401-018-1933-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1933-9</ArticleId><ArticleId IdType="pmc">PMC6482122</ArticleId><ArticleId IdType="pubmed">30465257</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers D.R., Appel S.H. Immune dysregulation in amyotrophic lateral sclerosis: Mechanisms and emerging therapies. Lancet Neurol. 2019;18:211&#x2013;220. doi: 10.1016/S1474-4422(18)30394-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30394-6</ArticleId><ArticleId IdType="pubmed">30663610</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejzini R., Flynn L.L., Pitout I.L., Fletcher S., Wilton S.D., Akkari P.A. ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now? Front. Neurosci. 2019;13:1310. doi: 10.3389/fnins.2019.01310.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.01310</ArticleId><ArticleId IdType="pmc">PMC6909825</ArticleId><ArticleId IdType="pubmed">31866818</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood A., Gurfinkel Y., Polain N., Lamont W., Lyn Rea S. Molecular Mechanisms Underlying TDP-43 Pathology in Cellular and Animal Models of ALS and FTLD. Int. J. Mol. Sci. 2021;22:4705. doi: 10.3390/ijms22094705.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22094705</ArticleId><ArticleId IdType="pmc">PMC8125728</ArticleId><ArticleId IdType="pubmed">33946763</ArticleId></ArticleIdList></Reference><Reference><Citation>Ransohoff R.M. How neuroinflammation contributes to neurodegeneration. Science. 2016;353:777&#x2013;783. doi: 10.1126/science.aag2590.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aag2590</ArticleId><ArticleId IdType="pubmed">27540165</ArticleId></ArticleIdList></Reference><Reference><Citation>Lomen-Hoerth C., Anderson T., Miller B. The overlap of amyotrophic lateral sclerosis and frontotemporal dementia. Neurology. 2002;59:1077&#x2013;1079. doi: 10.1212/WNL.59.7.1077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.59.7.1077</ArticleId><ArticleId IdType="pubmed">12370467</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong M.J., Grace G.M., Freedman M., Lomen-Hoerth C., Woolley S., Goldstein L.H., Murphy J., Shoesmith C., Rosenfeld J., Leigh P.N., et al. Consensus criteria for the diagnosis of frontotemporal cognitive and behavioural syndromes in amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. 2009;10:131&#x2013;146. doi: 10.1080/17482960802654364.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960802654364</ArticleId><ArticleId IdType="pubmed">19462523</ArticleId></ArticleIdList></Reference><Reference><Citation>Abramzon Y.A., Fratta P., Traynor B.J., Chia R. The Overlapping Genetics of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Front. Neurosci. 2020;14:42. doi: 10.3389/fnins.2020.00042.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2020.00042</ArticleId><ArticleId IdType="pmc">PMC7012787</ArticleId><ArticleId IdType="pubmed">32116499</ArticleId></ArticleIdList></Reference><Reference><Citation>Mannini B., Vecchi G., Labrador-Garrido A., Fabre B., Fani G., Franco J.M., Lilley K., Pozo D., Vendruscolo M., Chiti F., et al. Differential Interactome and Innate Immune Response Activation of Two Structurally Distinct Misfolded Protein Oligomers. ACS Chem. Neurosci. 2019;10:3464&#x2013;3478. doi: 10.1021/acschemneuro.9b00088.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.9b00088</ArticleId><ArticleId IdType="pubmed">31313906</ArticleId></ArticleIdList></Reference><Reference><Citation>Leal-Lasarte M., Mannini B., Chiti F., Vendruscolo M., Dobson C.M., Roodveldt C., Pozo D. Distinct responses of human peripheral blood cells to different misfolded protein oligomers. Immunology. 2021;64:358&#x2013;371. doi: 10.1111/imm.13377.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imm.13377</ArticleId><ArticleId IdType="pmc">PMC8442237</ArticleId><ArticleId IdType="pubmed">34043816</ArticleId></ArticleIdList></Reference><Reference><Citation>Haukedal H., Freude K. Implications of Microglia in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. J. Mol. Biol. 2019;431:1818&#x2013;1829. doi: 10.1016/j.jmb.2019.02.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2019.02.004</ArticleId><ArticleId IdType="pubmed">30763568</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo W., Vandoorne T., Steyaert J., Staats K.A., Van Den Bosch L. The multifaceted role of kinases in amyotrophic lateral sclerosis: Genetic, pathological and therapeutic implications. Brain. 2020;143:1651&#x2013;1673. doi: 10.1093/brain/awaa022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa022</ArticleId><ArticleId IdType="pmc">PMC7296858</ArticleId><ArticleId IdType="pubmed">32206784</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirulli E.T., Lasseigne B.N., Petrovski S., Sapp P.C., Dion P.A., Leblond C.S., Couthouis J., Lu Y.F., Wang Q., Krueger B.J., et al. Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. Science. 2015;347:1436&#x2013;1441. doi: 10.1126/science.aaa3650.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaa3650</ArticleId><ArticleId IdType="pmc">PMC4437632</ArticleId><ArticleId IdType="pubmed">25700176</ArticleId></ArticleIdList></Reference><Reference><Citation>Freischmidt A., Wieland T., Richter B., Ruf W., Schaeffer V., M&#xfc;ller K., Marroquin N., Nordin F., H&#xfc;bers A., Weydt P., et al. Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. Nat. Neurosci. 2015;18:631&#x2013;636. doi: 10.1038/nn.4000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4000</ArticleId><ArticleId IdType="pubmed">25803835</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakes J.A., Davies M.C., Collins M.O. TBK1: A new player in ALS linking autophagy and neuroinflammation. Mol. Brain. 2017;10:5. doi: 10.1186/s13041-017-0287-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13041-017-0287-x</ArticleId><ArticleId IdType="pmc">PMC5288885</ArticleId><ArticleId IdType="pubmed">28148298</ArticleId></ArticleIdList></Reference><Reference><Citation>Gijselinck I., Van Mossevelde S., van der Zee J., Sieben A., Philtjens S., Heeman B., Engelborghs S., Vandenbulcke M., De Baets G., B&#xe4;umer V., et al. Loss of TBK1 is a frequent cause of frontotemporal dementia in a Belgian cohort. Neurology. 2015;85:2116&#x2013;2125. doi: 10.1212/WNL.0000000000002220.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002220</ArticleId><ArticleId IdType="pmc">PMC4691687</ArticleId><ArticleId IdType="pubmed">26581300</ArticleId></ArticleIdList></Reference><Reference><Citation>Pottier C., Bieniek K.F., Finch N., van de Vorst M., Baker M., Perkersen R., Brown P., Ravenscroft T., van Blitterswijk M., Nicholson A.M., et al. Whole-genome sequencing reveals important role for TBK1 and OPTN mutations in frontotemporal lobar degeneration without motor neuron disease. Acta Neuropathol. 2015;130:77&#x2013;92. doi: 10.1007/s00401-015-1436-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-015-1436-x</ArticleId><ArticleId IdType="pmc">PMC4470809</ArticleId><ArticleId IdType="pubmed">25943890</ArticleId></ArticleIdList></Reference><Reference><Citation>de Majo M., Topp S.D., Smith B.N., Nishimura A.L., Chen H.J., Gkazi A.S., Miller J., Wong C.H., Vance C., Baas F., et al. ALS-associated missense and nonsense TBK1 mutations can both cause loss of kinase function. Neurobiol. Aging. 2018;71:266.e1&#x2013;266.e10. doi: 10.1016/j.neurobiolaging.2018.06.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2018.06.015</ArticleId><ArticleId IdType="pmc">PMC6983933</ArticleId><ArticleId IdType="pubmed">30033073</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan W., Guo M., Yi L., Zhang J., Bi Y., Liu Y., Li Y., Li Z., Ma Y., Zhang G., et al. Deletion of Tbk1 disrupts autophagy and reproduces behavioral and locomotor symptoms of FTD-ALS in mice. Aging. 2019;11:2457&#x2013;2476. doi: 10.18632/aging.101936.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.101936</ArticleId><ArticleId IdType="pmc">PMC6519994</ArticleId><ArticleId IdType="pubmed">31039129</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Zee J., Gijselinck I., Van Mossevelde S., Perrone F., Dillen L., Heeman B., B&#xe4;umer V., Engelborghs S., De Bleecker J., Baets J., et al. TBK1 Mutation Spectrum in an Extended European Patient Cohort with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. Hum. Mutat. 2017;38:297&#x2013;309. doi: 10.1002/humu.23161.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.23161</ArticleId><ArticleId IdType="pmc">PMC5324646</ArticleId><ArticleId IdType="pubmed">28008748</ArticleId></ArticleIdList></Reference><Reference><Citation>Foster A.D., Downing P., Figredo E., Polain N., Stott A., Layfield R., Rea S.L. ALS-associated TBK1 variant p.G175S is defective in phosphorylation of p62 and impacts TBK1-mediated signalling and TDP-43 autophagic degradation. Mol. Cell. Neurosci. 2020;108:103539. doi: 10.1016/j.mcn.2020.103539.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2020.103539</ArticleId><ArticleId IdType="pubmed">32835772</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore A.S., Holzbaur E.L. Dynamic recruitment and activation of ALS-associated TBK1 with its target optineurin are required for efficient mitophagy. Proc. Natl. Acad. Sci. USA. 2016;113:E3349&#x2013;E3358. doi: 10.1073/pnas.1523810113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1523810113</ArticleId><ArticleId IdType="pmc">PMC4914160</ArticleId><ArticleId IdType="pubmed">27247382</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmad L., Zhang S.Y., Casanova J.L., Sancho-Shimizu V. Human TBK1: A Gatekeeper of Neuroinflammation. Trends Mol. Med. 2016;22:511&#x2013;527. doi: 10.1016/j.molmed.2016.04.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2016.04.006</ArticleId><ArticleId IdType="pmc">PMC4890605</ArticleId><ArticleId IdType="pubmed">27211305</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye J., Cheung J., Gerbino V., Ahls&#xe9;n G., Zimanyi C., Hirsh D., Maniatis T. Effects of ALS-associated TANK binding kinase 1 mutations on protein-protein interactions and kinase activity. Proc. Natl. Acad. Sci. USA. 2019;116:24517&#x2013;24526. doi: 10.1073/pnas.1915732116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1915732116</ArticleId><ArticleId IdType="pmc">PMC6900539</ArticleId><ArticleId IdType="pubmed">31748271</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu D., Jin T., Zhu H., Chen H., Ofengeim D., Zou C., Mifflin L., Pan L., Amin P., Li W., et al. TBK1 Suppresses RIPK1-Driven Apoptosis and Inflammation during Development and in Aging. Cell. 2018;174:1477&#x2013;1491.e19. doi: 10.1016/j.cell.2018.07.041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.07.041</ArticleId><ArticleId IdType="pmc">PMC6128749</ArticleId><ArticleId IdType="pubmed">30146158</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner D., Sieverding K., Bruno C., L&#xfc;ningschr&#xf6;r P., Buck E., Mungwa S., Fischer L., Brockmann S.J., Ulmer J., Bliederh&#xe4;user C., et al. Heterozygous Tbk1 loss has opposing effects in early and late stages of ALS in mice. J. Exp. Med. 2019;216:267&#x2013;278. doi: 10.1084/jem.20180729.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20180729</ArticleId><ArticleId IdType="pmc">PMC6363427</ArticleId><ArticleId IdType="pubmed">30635357</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerbino V., Kaunga E., Ye J., Canzio D., O&#x2019;Keeffe S., Rudnick N.D., Guarnieri P., Lutz C.M., Maniatis T. The Loss of TBK1 Kinase Activity in Motor Neurons or in All Cell Types Differentially Impacts ALS Disease Progression in SOD1 Mice. Neuron. 2020;106:789&#x2013;805.e5. doi: 10.1016/j.neuron.2020.03.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2020.03.005</ArticleId><ArticleId IdType="pubmed">32220666</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan J., Amin P., Ofengeim D. Necroptosis and RIPK1-mediated neuroinflammation in CNS diseases. Nat. Rev. Neurosci. 2019;20:19&#x2013;33. doi: 10.1038/s41583-018-0093-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41583-018-0093-1</ArticleId><ArticleId IdType="pmc">PMC6342007</ArticleId><ArticleId IdType="pubmed">30467385</ArticleId></ArticleIdList></Reference><Reference><Citation>Humphries F., Yang S., Wang B., Moynagh P.N. RIP kinases: Key decision makers in cell death and innate immunity. Cell Death Differ. 2015;22:225&#x2013;236. doi: 10.1038/cdd.2014.126.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cdd.2014.126</ArticleId><ArticleId IdType="pmc">PMC4291486</ArticleId><ArticleId IdType="pubmed">25146926</ArticleId></ArticleIdList></Reference><Reference><Citation>Christofferson D.E., Li Y., Hitomi J., Zhou W., Upperman C., Zhu H., Gerber S.A., Gygi S., Yuan J. A novel role for RIP1 kinase in mediating TNF&#x3b1; production. Cell Death Dis. 2012;3:e320. doi: 10.1038/cddis.2012.64.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cddis.2012.64</ArticleId><ArticleId IdType="pmc">PMC3388236</ArticleId><ArticleId IdType="pubmed">22695613</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito Y., Ofengeim D., Najafov A., Das S., Saberi S., Li Y., Hitomi J., Zhu H., Chen H., Mayo L., et al. RIPK1 mediates axonal degeneration by promoting inflammation and necroptosis in ALS. Science. 2016;353:603&#x2013;608. doi: 10.1126/science.aaf6803.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaf6803</ArticleId><ArticleId IdType="pmc">PMC5444917</ArticleId><ArticleId IdType="pubmed">27493188</ArticleId></ArticleIdList></Reference><Reference><Citation>Mifflin L., Hu Z., Dufort C., Hession C.C., Walker A.J., Niu K., Zhu H., Liu N., Liu J.S., Levin J.Z., et al. A RIPK1-regulated inflammatory microglial state in amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA. 2021;118:e2025102118. doi: 10.1073/pnas.2025102118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2025102118</ArticleId><ArticleId IdType="pmc">PMC8020785</ArticleId><ArticleId IdType="pubmed">33766915</ArticleId></ArticleIdList></Reference><Reference><Citation>Kania A., Klein R. Mechanisms of ephrin-Eph signalling in development, physiology and disease. Nat. Rev. Mol. Cell Biol. 2016;17:240&#x2013;256. doi: 10.1038/nrm.2015.16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm.2015.16</ArticleId><ArticleId IdType="pubmed">26790531</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Hoecke A., Schoonaert L., Lemmens R., Timmers M., Staats K.A., Laird A.S., Peeters E., Philips T., Goris A., Dubois B., et al. EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in humans. Nat. Med. 2012;18:1418&#x2013;1422. doi: 10.1038/nm.2901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.2901</ArticleId><ArticleId IdType="pubmed">22922411</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldshmit Y., Galea M.P., Wise G., Bartlett P.F., Turnley A.M. Axonal regeneration and lack of astrocytic gliosis in EphA4-deficient mice. J. Neurosci. 2004;24:10064&#x2013;10073. doi: 10.1523/JNEUROSCI.2981-04.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2981-04.2004</ArticleId><ArticleId IdType="pmc">PMC6730186</ArticleId><ArticleId IdType="pubmed">15537875</ArticleId></ArticleIdList></Reference><Reference><Citation>Kowalski E.A., Chen J., Hazy A., Fritsch L.E., Gudenschwager-Basso E.K., Chen M., Wang X., Qian Y., Zhou M., Byerly M., et al. Peripheral loss of EphA4 ameliorates TBI-induced neuroinflammation and tissue damage. J. Neuroinflamm. 2019;16:210. doi: 10.1186/s12974-019-1605-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-019-1605-2</ArticleId><ArticleId IdType="pmc">PMC6844068</ArticleId><ArticleId IdType="pubmed">31711546</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoonaert L., Ru&#xe9; L., Roucourt B., Timmers M., Little S., Ch&#xe1;vez-Guti&#xe9;rrez L., Dewilde M., Joyce P., Curnock A., Weber P., et al. Identification and characterization of Nanobodies targeting the EphA4 receptor. J. Biol. Chem. 2017;292:11452&#x2013;11465. doi: 10.1074/jbc.M116.774141.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M116.774141</ArticleId><ArticleId IdType="pmc">PMC5500810</ArticleId><ArticleId IdType="pubmed">28526745</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J., Cooper L.T., Boyd A.W., Bartlett P.F. Decreased signalling of EphA4 improves functional performance and motor neuron survival in the SOD1 G93A ALS mouse model. Sci. Rep. 2018;8:11393. doi: 10.1038/s41598-018-29845-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-29845-1</ArticleId><ArticleId IdType="pmc">PMC6065374</ArticleId><ArticleId IdType="pubmed">30061574</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu B., De S.K., Kulinich A., Salem A.F., Koeppen, Wang R., Barile E., Wang S., Zhang D., Ethell I., et al. Potent and Selective EphA4 Agonists for the Treatment of ALS. Cell Chem. Biol. 2017;24:293&#x2013;305. doi: 10.1016/j.chembiol.2017.01.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chembiol.2017.01.006</ArticleId><ArticleId IdType="pmc">PMC6522132</ArticleId><ArticleId IdType="pubmed">28196613</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling K.K., Jackson M., Alkam D., Liu D., Allaire N., Sun C., Kiaei M., McCampbell A., Rigo F. Antisense-mediated reduction of EphA4 in the adult CNS does not improve the function of mice with amyotrophic lateral sclerosis. Neurobiol. Dis. 2018;114:174&#x2013;183. doi: 10.1016/j.nbd.2018.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2018.03.002</ArticleId><ArticleId IdType="pubmed">29518482</ArticleId></ArticleIdList></Reference><Reference><Citation>Ru&#xe9; L., Timmers M., Lenaerts A., Smolders S., Poppe L., de Boer A., Van Den Bosch L., Van Damme P., Robberecht W., Lemmens R. Reducing EphA4 before disease onset does not affect survival in a mouse model of Amyotrophic Lateral Sclerosis. Sci. Rep. 2019;9:14112. doi: 10.1038/s41598-019-50615-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-50615-0</ArticleId><ArticleId IdType="pmc">PMC6773754</ArticleId><ArticleId IdType="pubmed">31575928</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyzack G.E., Hall C.E., Sibley, Cymes T., Forostyak S., Carlino G., Meyer I.F., Schiavo G., Zhang S.C., Gibbons G.M., et al. A neuroprotective astrocyte state is induced by neuronal signal EphB1 but fails in ALS models. Nat. Commun. 2017;8:1164. doi: 10.1038/s41467-017-01283-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-01283-z</ArticleId><ArticleId IdType="pmc">PMC5660125</ArticleId><ArticleId IdType="pubmed">29079839</ArticleId></ArticleIdList></Reference><Reference><Citation>Russo A., Scardigli R., La Regina F., Murray M.E., Romano N., Dickson D.W., Wolozin B., Cattaneo A., Ceci M. Increased cytoplasmic TDP-43 reduces global protein synthesis by interacting with RACK1 on polyribosomes. Hum. Mol. Genet. 2017;26:1407&#x2013;1418. doi: 10.1093/hmg/ddx035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddx035</ArticleId><ArticleId IdType="pmc">PMC6075552</ArticleId><ArticleId IdType="pubmed">28158562</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin H., Song S., Pan X. Knockdown of miR-155 protects microglia against LPS-induced inflammatory injury via targeting RACK1: A novel research for intracranial infection. J. Inflamm. 2017;14:17. doi: 10.1186/s12950-017-0162-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12950-017-0162-7</ArticleId><ArticleId IdType="pmc">PMC5549339</ArticleId><ArticleId IdType="pubmed">28804270</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan Y., Zhang L., Angosto-Bazarra D., Pelegr&#xed;n P., N&#xfa;&#xf1;ez G., He Y. RACK1 Mediates NLRP3 Inflammasome Activation by Promoting NLRP3 Active Conformation and Inflammasome Assembly. Cell Rep. 2020;33:108405. doi: 10.1016/j.celrep.2020.108405.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2020.108405</ArticleId><ArticleId IdType="pmc">PMC7709964</ArticleId><ArticleId IdType="pubmed">33207200</ArticleId></ArticleIdList></Reference><Reference><Citation>Perera N.D., Turner B.J. AMPK Signalling and Defective Energy Metabolism in Amyotrophic Lateral Sclerosis. Neurochem. Res. 2016;41:544&#x2013;553. doi: 10.1007/s11064-015-1665-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-015-1665-3</ArticleId><ArticleId IdType="pubmed">26202426</ArticleId></ArticleIdList></Reference><Reference><Citation>Beckers J., Tharkeshwar A.K., Van Damme P. C9orf72 ALS-FTD: Recent evidence for dysregulation of the autophagy-lysosome pathway at multiple levels. Autophagy. 2021;17:3306&#x2013;3322. doi: 10.1080/15548627.2021.1872189.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15548627.2021.1872189</ArticleId><ArticleId IdType="pmc">PMC8632097</ArticleId><ArticleId IdType="pubmed">33632058</ArticleId></ArticleIdList></Reference><Reference><Citation>Root J., Merino P., Nuckols A., Johnson M., Kukar T. Lysosome dysfunction as a cause of neurodegenerative diseases: Lessons from frontotemporal dementia and amyotrophic lateral sclerosis. Neurobiol. Dis. 2021;154:105360. doi: 10.1016/j.nbd.2021.105360.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2021.105360</ArticleId><ArticleId IdType="pmc">PMC8113138</ArticleId><ArticleId IdType="pubmed">33812000</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito M., Saito M., Das B.C. Involvement of AMP-activated protein kinase in neuroinflammation and neurodegeneration in the adult and developing brain. Int. J. Dev. Neurosci. 2019;77:48&#x2013;59. doi: 10.1016/j.ijdevneu.2019.01.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijdevneu.2019.01.007</ArticleId><ArticleId IdType="pmc">PMC6663660</ArticleId><ArticleId IdType="pubmed">30707928</ArticleId></ArticleIdList></Reference><Reference><Citation>Broce I., Karch C.M., Wen N., Fan C.C., Wang Y., Tan C.H., Kouri N., Ross O.A., H&#xf6;glinger G.U., Muller U., et al. Immune-related genetic enrichment in frontotemporal dementia: An analysis of genome-wide association studies. PLoS Med. 2018;15:e1002487. doi: 10.1371/JOURNAL.PMED.1002487.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/JOURNAL.PMED.1002487</ArticleId><ArticleId IdType="pmc">PMC5760014</ArticleId><ArticleId IdType="pubmed">29315334</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xe4;chsel J.C., Ross O.A., Mata I.F., Kachergus J., Toft M., Cannon A., Baker M., Adamson J., Hutton M., Dickson D.W., et al. Lrrk2 G2019S substitution in frontotemporal lobar degeneration with ubiquitin-immunoreactive neuronal inclusions. Acta Neuropathol. 2007;113:601&#x2013;606. doi: 10.1007/s00401-006-0178-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-006-0178-1</ArticleId><ArticleId IdType="pubmed">17151837</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrari R., Wang Y., Vandrovcova J., Guelfi S., Witeolar A., Karch C.M., Schork A.J., Fan C.C., Brewer J.B., Momeni P., et al. Genetic architecture of sporadic frontotemporal dementia and overlap with Alzheimer&#x2019;s and Parkinson&#x2019;s diseases. J. Neurol. Neurosurg. Psychiatry. 2017;88:152&#x2013;164. doi: 10.1136/JNNP-2016-314411.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/JNNP-2016-314411</ArticleId><ArticleId IdType="pmc">PMC5237405</ArticleId><ArticleId IdType="pubmed">27899424</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciani M., Bonvicini C., Scassellati C., Carrara M., Maj C., Fostinelli S., Binetti G., Ghidoni R., Benussi L. The Missing Heritability of Sporadic Frontotemporal Dementia: New Insights from Rare Variants in Neurodegenerative Candidate Genes. Int. J. Mol. Sci. 2019;20:3903. doi: 10.3390/ijms20163903.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20163903</ArticleId><ArticleId IdType="pmc">PMC6721049</ArticleId><ArticleId IdType="pubmed">31405128</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmadi Rastegar D., Dzamko N. Leucine Rich Repeat Kinase 2 and Innate Immunity. Front. Neurosci. 2020;14:193. doi: 10.3389/fnins.2020.00193.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2020.00193</ArticleId><ArticleId IdType="pmc">PMC7077357</ArticleId><ArticleId IdType="pubmed">32210756</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallings R.L., Tansey M.G. LRRK2 regulation of immune-pathways and inflammatory disease. Biochem. Soc. Trans. 2019;47:1581&#x2013;1595. doi: 10.1042/BST20180463.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BST20180463</ArticleId><ArticleId IdType="pmc">PMC6925522</ArticleId><ArticleId IdType="pubmed">31769472</ArticleId></ArticleIdList></Reference><Reference><Citation>Gloeckner C.J., Schumacher A., Boldt K., Ueffing M. The Parkinson disease-associated protein kinase LRRK2 exhibits MAPKKK activity and phosphorylates MKK3/6 and MKK4/7, in vitro. J. Neurochem. 2009;109:959&#x2013;968. doi: 10.1111/j.1471-4159.2009.06024.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2009.06024.x</ArticleId><ArticleId IdType="pubmed">19302196</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu C.H., Chan D., Wolozin B. LRRK2 and the stress response: Interaction with MKKs and JNK-interacting proteins. Neurodegener. Dis. 2010;7:68&#x2013;75. doi: 10.1159/000285509.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000285509</ArticleId><ArticleId IdType="pmc">PMC2859233</ArticleId><ArticleId IdType="pubmed">20173330</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C.Y., Weng Y.H., Chien K.Y., Lin K.J., Yeh T.H., Cheng Y.P., Lu C.S., Wang H.L. (G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD. Cell Death Differ. 2012;19:1623&#x2013;1633. doi: 10.1038/cdd.2012.42.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cdd.2012.42</ArticleId><ArticleId IdType="pmc">PMC3438494</ArticleId><ArticleId IdType="pubmed">22539006</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z., Lee J., Krummey S., Lu W., Cai H., Lenardo M.J. The kinase LRRK2 is a regulator of the transcription factor NFAT that modulates the severity of inflammatory bowel disease. Nat. Immunol. 2011;12:1063&#x2013;1070. doi: 10.1038/ni.2113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.2113</ArticleId><ArticleId IdType="pmc">PMC4140245</ArticleId><ArticleId IdType="pubmed">21983832</ArticleId></ArticleIdList></Reference><Reference><Citation>Panagiotakopoulou V., Ivanyuk D., De Cicco S., Haq W., Arsi&#x107; A., Yu C., Messelodi D., Oldrati M., Sch&#xf6;ndorf D.C., Perez M.J., et al. Interferon-&#x3b3; signaling synergizes with LRRK2 in neurons and microglia derived from human induced pluripotent stem cells. Nat. Commun. 2020;11:5163. doi: 10.1038/s41467-020-18755-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-18755-4</ArticleId><ArticleId IdType="pmc">PMC7560616</ArticleId><ArticleId IdType="pubmed">33057020</ArticleId></ArticleIdList></Reference><Reference><Citation>Takagawa T., Kitani A., Fuss I., Levine B., Brant S.R., Peter I., Tajima M., Nakamura S., Strober W. An increase in LRRK2 suppresses autophagy and enhances Dectin-1-induced immunity in a mouse model of colitis. Sci. Transl. Med. 2018;10:eaan8162. doi: 10.1126/scitranslmed.aan8162.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aan8162</ArticleId><ArticleId IdType="pmc">PMC6636639</ArticleId><ArticleId IdType="pubmed">29875204</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W., Liu X., Li Y., Zhao J., Liu Z., Hu Z., Wang Y., Yao Y., Miller A.W., Su B., et al. LRRK2 promotes the activation of NLRC4 inflammasome during Salmonella Typhimurium infection. J. Exp. Med. 2017;214:3051&#x2013;3066. doi: 10.1084/jem.20170014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20170014</ArticleId><ArticleId IdType="pmc">PMC5626397</ArticleId><ArticleId IdType="pubmed">28821568</ArticleId></ArticleIdList></Reference><Reference><Citation>Russo I., Berti G., Plotegher N., Bernardo G., Filograna R., Bubacco L., Greggio E. Leucine-rich repeat kinase 2 positively regulates inflammation and down-regulates NF-&#x3ba;B p50 signaling in cultured microglia cells. J. Neuroinflamm. 2015;12:230. doi: 10.1186/s12974-015-0449-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-015-0449-7</ArticleId><ArticleId IdType="pmc">PMC4673731</ArticleId><ArticleId IdType="pubmed">26646749</ArticleId></ArticleIdList></Reference><Reference><Citation>Russo I., Di Benedetto G., Kaganovich A., Ding J., Mercatelli D., Morari M., Cookson M.R., Bubacco L., Greggio E. Leucine-rich repeat kinase 2 controls protein kinase A activation state through phosphodiesterase 4. J. Neuroinflamm. 2018;15:297. doi: 10.1186/s12974-018-1337-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-018-1337-8</ArticleId><ArticleId IdType="pmc">PMC6204045</ArticleId><ArticleId IdType="pubmed">30368241</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho C.C.-Y., Rideout H.J., Ribe E., Troy C.M., Dauer W.T. The Parkinson Disease Protein Leucine-Rich Repeat Kinase 2 Transduces Death Signals via Fas-Associated Protein with Death Domain and Caspase-8 in a Cellular Model of Neurodegeneration. J. Neurosci. 2009;29:1011. doi: 10.1523/JNEUROSCI.5175-08.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5175-08.2009</ArticleId><ArticleId IdType="pmc">PMC2768412</ArticleId><ArticleId IdType="pubmed">19176810</ArticleId></ArticleIdList></Reference><Reference><Citation>Amin P., Florez M., Najafov A., Pan H., Geng J., Ofengeim D., Dziedzic S.A., Wang H., Barrett V.J., Ito Y., et al. Regulation of a distinct activated RIPK1 intermediate bridging complex I and complex II in TNF&#x3b1;-mediated apoptosis. Proc. Natl. Acad. Sci. USA. 2018;115:E5944. doi: 10.1073/pnas.1806973115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1806973115</ArticleId><ArticleId IdType="pmc">PMC6042106</ArticleId><ArticleId IdType="pubmed">29891719</ArticleId></ArticleIdList></Reference><Reference><Citation>Balachandran S., Roberts P.C., Brown L.E., Truong H., Pattnaik A.K., Archer D.R., Barber G.N. Essential role for the dsRNA-dependent protein kinase PKR in innate immunity to viral infection. Immunity. 2000;13:129&#x2013;141. doi: 10.1016/S1074-7613(00)00014-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1074-7613(00)00014-5</ArticleId><ArticleId IdType="pubmed">10933401</ArticleId></ArticleIdList></Reference><Reference><Citation>Prudencio M., Gonzales P.K., Cook C.N., Gendron T.F., Daughrity L.M., Song Y., Ebbert M.T.W., van Blitterswijk M., Zhang Y.J., Jansen-West K., et al. Repetitive element transcripts are elevated in the brain of C9orf72 ALS/FTLD patients. Hum. Mol. Genet. 2017;26:3421&#x2013;3431. doi: 10.1093/hmg/ddx233.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddx233</ArticleId><ArticleId IdType="pmc">PMC5886204</ArticleId><ArticleId IdType="pubmed">28637276</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W., Jin Y., Prazak L., Hammell M., Dubnau J. Transposable elements in TDP-43-mediated neurodegenerative disorders. PLoS ONE. 2012;7:e44099. doi: 10.1371/journal.pone.0044099.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0044099</ArticleId><ArticleId IdType="pmc">PMC3434193</ArticleId><ArticleId IdType="pubmed">22957047</ArticleId></ArticleIdList></Reference><Reference><Citation>LaRocca T.J., Mariani A., Watkins L.R., Link C.D. TDP-43 knockdown causes innate immune activation via protein kinase R in astrocytes. Neurobiol. Dis. 2019;132:104514. doi: 10.1016/j.nbd.2019.104514.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2019.104514</ArticleId><ArticleId IdType="pmc">PMC6834892</ArticleId><ArticleId IdType="pubmed">31229690</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu J.H., Zhang H., Wagey R., Krieger C., Pelech S.L. Protein kinase and protein phosphatase expression in amyotrophic lateral sclerosis spinal cord. J. Neurochem. 2003;85:432&#x2013;442. doi: 10.1046/j.1471-4159.2003.01670.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.2003.01670.x</ArticleId><ArticleId IdType="pubmed">12675919</ArticleId></ArticleIdList></Reference><Reference><Citation>Zu T., Guo S., Bardhi O., Ryskamp D.A., Li J., Khoramian Tusi S., Engelbrecht A., Klippel K., Chakrabarty P., Nguyen L., et al. Metformin inhibits RAN translation through PKR pathway and mitigates disease in C9orf72 ALS/FTD mice. Proc. Natl. Acad. Sci. USA. 2020;117:18591&#x2013;18599. doi: 10.1073/pnas.2005748117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2005748117</ArticleId><ArticleId IdType="pmc">PMC7414156</ArticleId><ArticleId IdType="pubmed">32690681</ArticleId></ArticleIdList></Reference><Reference><Citation>Ash P.E., Bieniek K.F., Gendron T.F., Caulfield T., Lin W.L., Dejesus-Hernandez M., van Blitterswijk M.M., Jansen-West K., Paul J.W., Rademakers R., et al. Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron. 2013;77:639&#x2013;646. doi: 10.1016/j.neuron.2013.02.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.02.004</ArticleId><ArticleId IdType="pmc">PMC3593233</ArticleId><ArticleId IdType="pubmed">23415312</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori K., Weng S.M., Arzberger T., May S., Rentzsch K., Kremmer E., Schmid B., Kretzschmar H.A., Cruts M., Van Broeckhoven C., et al. The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science. 2013;339:1335&#x2013;1338. doi: 10.1126/science.1232927.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1232927</ArticleId><ArticleId IdType="pubmed">23393093</ArticleId></ArticleIdList></Reference><Reference><Citation>Zu T., Liu Y., Ba&#xf1;ez-Coronel M., Reid T., Pletnikova O., Lewis J., Miller T.M., Harms M.B., Falchook A.E., Subramony S.H., et al. RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proc. Natl. Acad. Sci. USA. 2013;110:E4968&#x2013;E4977. doi: 10.1073/pnas.1315438110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1315438110</ArticleId><ArticleId IdType="pmc">PMC3870665</ArticleId><ArticleId IdType="pubmed">24248382</ArticleId></ArticleIdList></Reference><Reference><Citation>Leal-Lasarte M.M., Franco J.M., Labrador-Garrido A., Pozo D., Roodveldt C. Extracellular TDP-43 aggregates target MAPK/MAK/MRK overlapping kinase (MOK) and trigger caspase-3/IL-18 signaling in microglia. FASEB J. 2017;31:2797&#x2013;2816. doi: 10.1096/fj.201601163R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.201601163R</ArticleId><ArticleId IdType="pubmed">28336525</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyata Y., Akashi M., Nishida E. Molecular cloning and characterization of a novel member of the MAP kinase superfamily. Genes Cells. 1999;4:299&#x2013;309. doi: 10.1046/j.1365-2443.1999.00261.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2443.1999.00261.x</ArticleId><ArticleId IdType="pubmed">10421840</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu Z. Protein Kinases. InTech; London, UK: 2012. Regulations and Functions of ICK/MAK/MOK&#x2014;A Novel MAPK-Related Kinase Family Linked to Human Diseases.</Citation></Reference><Reference><Citation>Panza F., Lozupone M., Seripa D., Daniele A., Watling M., Giannelli G., Imbimbo B.P. Development of disease-modifying drugs for frontotemporal dementia spectrum disorders. Nat. Rev. Neurol. 2020;16:213&#x2013;228. doi: 10.1038/s41582-020-0330-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-020-0330-x</ArticleId><ArticleId IdType="pubmed">32203398</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaiswalv M.K. Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs. Med. Res. Rev. 2019;39:733&#x2013;748. doi: 10.1002/med.21528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/med.21528</ArticleId><ArticleId IdType="pubmed">30101496</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheah B.C., Vucic S., Krishnan A.V., Kiernan K. Riluzole, neuroprotection and amyotrophic lateral sclerosis. Curr. Med. Chem. 2010;17:1942&#x2013;1959. doi: 10.2174/092986710791163939.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/092986710791163939</ArticleId><ArticleId IdType="pubmed">20377511</ArticleId></ArticleIdList></Reference><Reference><Citation>Noh K.M., Hwang J.Y., Shin H.C., Koh J.Y. A novel neuroprotective mechanism of riluzole: Direct inhibition of protein kinase C. Neurobiol. Dis. 2000;7:375&#x2013;383. doi: 10.1006/nbdi.2000.0297.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/nbdi.2000.0297</ArticleId><ArticleId IdType="pubmed">10964608</ArticleId></ArticleIdList></Reference><Reference><Citation>Altman A., Kong K.F. Protein Kinase C Enzymes in the Hematopoietic and Immune Systems. Annu. Rev. Immunol. 2016;34:511&#x2013;538. doi: 10.1146/annurev-immunol-041015-055347.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-immunol-041015-055347</ArticleId><ArticleId IdType="pubmed">27168244</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubreuil P., Letard S., Ciufolini M., Gros L., Humbert M., Cast&#xe9;ran N., Borge L., Hajem B., Lermet A., Sippl W., et al. Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PLoS ONE. 2009;4:e7258. doi: 10.1371/journal.pone.0007258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0007258</ArticleId><ArticleId IdType="pmc">PMC2746281</ArticleId><ArticleId IdType="pubmed">19789626</ArticleId></ArticleIdList></Reference><Reference><Citation>Trias E., Ibarburu S., Barreto-N&#xfa;&#xf1;ez R., Babdor J., Maciel T.T., Guillo M., Gros L., Dubreuil P., D&#xed;az-Amarilla P., Cassina P., et al. Post-paralysis tyrosine kinase inhibition with masitinib abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral sclerosis. J. Neuroinflamm. 2016;13:177. doi: 10.1186/s12974-016-0620-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-016-0620-9</ArticleId><ArticleId IdType="pmc">PMC4940876</ArticleId><ArticleId IdType="pubmed">27400786</ArticleId></ArticleIdList></Reference><Reference><Citation>Palomo V., Nozal N., Rojas-Prats E., Gil C., Martinez A. Protein kinase inhibitors for amyotrophic lateral sclerosis therapy. Br. J. Pharmacol. 2021;178:1316&#x2013;1335. doi: 10.1111/bph.15221.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.15221</ArticleId><ArticleId IdType="pubmed">32737989</ArticleId></ArticleIdList></Reference><Reference><Citation>Liscic R.M., Alberici A., Cairns N.J., Romano M., Buratti E. From basic research to the clinic: Innovative therapies for ALS and FTD in the pipeline. Mol. Neurodegener. 2020;15:31. doi: 10.1186/s13024-020-00373-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-020-00373-9</ArticleId><ArticleId IdType="pmc">PMC7268618</ArticleId><ArticleId IdType="pubmed">32487123</ArticleId></ArticleIdList></Reference><Reference><Citation>Trias E., Ibarburu S., Barreto-N&#xfa;&#xf1;ez R., Varela V., Moura I.C., Dubreuil P., Hermine O., Beckman J.S., Barbeito L. Evidence for mast cells contributing to neuromuscular pathology in an inherited model of ALS. JCI Insight. 2017;2:e95934. doi: 10.1172/jci.insight.95934.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.95934</ArticleId><ArticleId IdType="pmc">PMC5846907</ArticleId><ArticleId IdType="pubmed">29046475</ArticleId></ArticleIdList></Reference><Reference><Citation>Trias E., King P.H., Si Y., Kwon Y., Varela V., Ibarburu S., Kovacs M., Moura I.C., Beckman J.S., Hermine O., et al. Mast cells and neutrophils mediate peripheral motor pathway degeneration in ALS. JCI Insight. 2018;3:3249. doi: 10.1172/jci.insight.123249.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.123249</ArticleId><ArticleId IdType="pmc">PMC6237484</ArticleId><ArticleId IdType="pubmed">30282815</ArticleId></ArticleIdList></Reference><Reference><Citation>Mora J.S., Genge A., Chio A., Estol C.J., Chaverri D., Hern&#xe1;ndez M., Mar&#xed;n S., Mascias J., Rodriguez G.E., Povedano M., et al. Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: A randomized clinical trial. Amyotroph. Lateral Scler. Frontotemporal. Degener. 2020;21:5&#x2013;14. doi: 10.1080/21678421.2019.1632346.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1632346</ArticleId><ArticleId IdType="pubmed">31280619</ArticleId></ArticleIdList></Reference><Reference><Citation>Roser A.E., T&#xf6;nges L., Lingor P. Modulation of Microglial Activity by Rho-Kinase (ROCK) Inhibition as Therapeutic Strategy in Parkinson&#x2019;s Disease and Amyotrophic Lateral Sclerosis. Front. Aging Neurosci. 2017;9:94. doi: 10.3389/fnagi.2017.00094.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2017.00094</ArticleId><ArticleId IdType="pmc">PMC5378706</ArticleId><ArticleId IdType="pubmed">28420986</ArticleId></ArticleIdList></Reference><Reference><Citation>Hensel N., Rademacher S., Claus P. Chatting with the neighbors: Crosstalk between Rho-kinase (ROCK) and other signaling pathways for treatment of neurological disorders. Front. Neurosci. 2015;9:198. doi: 10.3389/fnins.2015.00198.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2015.00198</ArticleId><ArticleId IdType="pmc">PMC4451340</ArticleId><ArticleId IdType="pubmed">26082680</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan J., Zhou X., Guo J.J., Mao L., Wang Y.J., Sun J., Sun L.X., Zhang L.Y., Zhou X.F., Liao H. Nogo-66 inhibits adhesion and migration of microglia via GTPase Rho pathway in vitro. J. Neurochem. 2012;120:721&#x2013;731. doi: 10.1111/j.1471-4159.2011.07619.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2011.07619.x</ArticleId><ArticleId IdType="pubmed">22145612</ArticleId></ArticleIdList></Reference><Reference><Citation>Borrajo A., Rodriguez-Perez A.I., Villar-Cheda B., Guerra M.J., Labandeira-Garcia J.L. Inhibition of the microglial response is essential for the neuroprotective effects of Rho-kinase inhibitors on MPTP-induced dopaminergic cell death. Neuropharmacology. 2014;85:1&#x2013;8. doi: 10.1016/j.neuropharm.2014.05.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2014.05.021</ArticleId><ArticleId IdType="pubmed">24878243</ArticleId></ArticleIdList></Reference><Reference><Citation>Conti A., Riva N., Pesca M., Iannaccone S., Cannistraci C.V., Corbo M., Previtali S.C., Quattrini A., Alessio M. Increased expression of Myosin binding protein H in the skeletal muscle of amyotrophic lateral sclerosis patients. Biochim. Biophys. Acta. 2014;1842:99&#x2013;106. doi: 10.1016/j.bbadis.2013.10.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2013.10.013</ArticleId><ArticleId IdType="pubmed">24184715</ArticleId></ArticleIdList></Reference><Reference><Citation>T&#xf6;nges L., G&#xfc;nther R., Suhr M., Jansen J., Balck A., Saal K.A., Barski E., Nientied T., G&#xf6;tz A.A., Koch J.C., et al. Rho kinase inhibition modulates microglia activation and improves survival in a model of amyotrophic lateral sclerosis. Glia. 2014;62:217&#x2013;232. doi: 10.1002/glia.22601.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.22601</ArticleId><ArticleId IdType="pubmed">24311453</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding J., Li Q.Y., Wang X., Sun C.H., Lu C.Z., Xiao B.G. Fasudil protects hippocampal neurons against hypoxia-reoxygenation injury by suppressing microglial inflammatory responses in mice. J. Neurochem. 2010;114:1619&#x2013;1629. doi: 10.1111/j.1471-4159.2010.06876.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2010.06876.x</ArticleId><ArticleId IdType="pubmed">20882700</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H., Li Y., Yu J., Guo M., Meng J., Liu C., Xie Y., Feng L., Xiao B., Ma C. Rho kinase inhibitor fasudil regulates microglia polarization and function. Neuroimmunomodulation. 2013;20:313&#x2013;322. doi: 10.1159/000351221.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000351221</ArticleId><ArticleId IdType="pubmed">23941863</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xfc;nther R., Balckv A., Koch J.C., Nientiedt T., Sereda M., B&#xe4;hr M., Lingor P., T&#xf6;nges L. Rho Kinase Inhibition with Fasudil in the SOD1 G93A Mouse Model of Amyotrophic Lateral Sclerosis-Symptomatic Treatment Potential after Disease Onset. Front. Pharmacol. 2017;8:17. doi: 10.3389/fphar.2017.00017.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2017.00017</ArticleId><ArticleId IdType="pmc">PMC5281550</ArticleId><ArticleId IdType="pubmed">28197100</ArticleId></ArticleIdList></Reference><Reference><Citation>Stankiewicz T.R., Pena C., Bouchard R., Linseman D.A. Dysregulation of Rac or Rho elicits death of motor neurons and activation of these GTPases is altered in the G93A mutant hSOD1 mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. 2020;136:104743. doi: 10.1016/j.nbd.2020.104743.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2020.104743</ArticleId><ArticleId IdType="pmc">PMC7020796</ArticleId><ArticleId IdType="pubmed">31931138</ArticleId></ArticleIdList></Reference><Reference><Citation>Joshi A.R., Muke I., Bobylev I., Lehmann H.C. ROCK inhibition improves axonal regeneration in a preclinical model of amyotrophic lateral sclerosis. J. Comp. Neurol. 2019;527:2334&#x2013;2340. doi: 10.1002/cne.24679.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cne.24679</ArticleId><ArticleId IdType="pubmed">30861116</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris P.A., Berger S.B., Jeong J.U., Nagilla R., Bandyopadhyay D., Campobasso N., Capriotti C.A., Cox J.A., Dare L., Dong X., et al. Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases. J. Med. Chem. 2017;60:1247&#x2013;1261. doi: 10.1021/acs.jmedchem.6b01751.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.6b01751</ArticleId><ArticleId IdType="pubmed">28151659</ArticleId></ArticleIdList></Reference><Reference><Citation>Mifflin L., Ofengeim D., Yuan J. Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target. Nat. Rev. Drug Discov. 2020;19:553&#x2013;571. doi: 10.1038/s41573-020-0071-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-020-0071-y</ArticleId><ArticleId IdType="pmc">PMC7362612</ArticleId><ArticleId IdType="pubmed">32669658</ArticleId></ArticleIdList></Reference><Reference><Citation>Globe Newswire by Notified.  [(accessed on 20 September 2021)].  Available online:  https://www.globenewswire.com/news-release/2020/06/09/2045940/0/en/Denali-Therapeutics-Provides-Broad-Update-on-Its-RIPK1-Program-Partnered-With-Sanofi.html.</Citation></Reference><Reference><Citation>ALS New Today.  [(accessed on 20 October 2021)].  Available online:  https://alsnewstoday.com/news-posts/2020/06/15/denali-sanofi-pause-dnl747-studies-favor-advancing-dnl788/</Citation></Reference><Reference><Citation>Beurel E. Regulation by glycogen synthase kinase-3 of inflammation and T cells in CNS diseases. Front. Mol. Neurosci. 2011;4:18. doi: 10.3389/fnmol.2011.00018.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2011.00018</ArticleId><ArticleId IdType="pmc">PMC3171068</ArticleId><ArticleId IdType="pubmed">21941466</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmeister L., Diekmann M., Brand K., Huber R. GSK3: A Kinase Balancing Promotion and Resolution of Inflammation. Cells. 2020;9:820. doi: 10.3390/cells9040820.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9040820</ArticleId><ArticleId IdType="pmc">PMC7226814</ArticleId><ArticleId IdType="pubmed">32231133</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong M., Chen D.C., Klein P.S., Lee V.M. Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3. J. Biol. Chem. 1997;272:25326&#x2013;25332. doi: 10.1074/jbc.272.40.25326.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.272.40.25326</ArticleId><ArticleId IdType="pubmed">9312151</ArticleId></ArticleIdList></Reference><Reference><Citation>Noble W., Planel E., Zehr C., Olm V., Meyerson J., Suleman F., Gaynor K., Wang L., LaFrancois J., Feinstein B., et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc. Natl. Acad. Sci. USA. 2005;102:6990&#x2013;6995. doi: 10.1073/pnas.0500466102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0500466102</ArticleId><ArticleId IdType="pmc">PMC1088065</ArticleId><ArticleId IdType="pubmed">15867159</ArticleId></ArticleIdList></Reference><Reference><Citation>Puglisi-Allegra S., Ruggieri S., Fornai F. Translational evidence for lithium-induced brain plasticity and neuroprotection in the treatment of neuropsychiatric disorders. Transl. Psychiatry. 2021;11:366. doi: 10.1038/s41398-021-01492-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41398-021-01492-7</ArticleId><ArticleId IdType="pmc">PMC8257731</ArticleId><ArticleId IdType="pubmed">34226487</ArticleId></ArticleIdList></Reference><Reference><Citation>NIH US Library of Medicine.  [(accessed on 20 October 2021)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT02862210.</Citation></Reference><Reference><Citation>Lv Z., Guo Y. Metformin and Its Benefits for Various Diseases. Front. Endocrinol. 2020;11:191. doi: 10.3389/fendo.2020.00191.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2020.00191</ArticleId><ArticleId IdType="pmc">PMC7212476</ArticleId><ArticleId IdType="pubmed">32425881</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaneb H.M., Sharp P.S., Rahmani-Kondori N., Wells D.J. Metformin treatment has no beneficial effect in a dose-response survival study in the SOD1(G93A) mouse model of ALS and is harmful in female mice. PLoS ONE. 2011;6:e24189. doi: 10.1371/journal.pone.0024189.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0024189</ArticleId><ArticleId IdType="pmc">PMC3164704</ArticleId><ArticleId IdType="pubmed">21909419</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters O.M., Ghasemi M., Brown R.H., Jr. Emerging mechanisms of molecular pathology in ALS. J. Clin. Investig. 2015;125:2548. doi: 10.1172/JCI82693.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI82693</ArticleId><ArticleId IdType="pmc">PMC4518693</ArticleId><ArticleId IdType="pubmed">26030230</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>